# Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

> **NCT04472429** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 308 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Anal Canal

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** retifanlimab

## Key facts

- **NCT ID:** NCT04472429
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2024-04-15
- **Final completion:** 2025-09-26
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472429, "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04472429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*